Constitutive and LPS-induced Expression of MCP-1 and IL-8 by Human Uveal Melanocytes in Vitro and Relevant Signal Pathways
Overview
Affiliations
Purpose: Melanocytes are one of the major cellular components in the uvea. Interleukin-8/CXCL8 and monocyte chemoattractant protein-1 (MCP-1/CCL2) are the two most important proinflammatory chemokines. We studied the constitutive and lipopolysaccharide (LPS)-induced expression of IL-8 and MCP-1 in cultured human uveal melanocytes (UM) and explored the relevant signal pathways.
Methods: Conditioned media and cells were collected from UM cultured in medium with and without stimulation of LPS. Interleukin-8 and MCP-1 proteins and mRNAs were measured using an ELISA kit and RT-PCR, respectively. Nuclear factor (NF)-κB in nuclear extracts and phosphorylated p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinases1/2 (ERK1/2), and c-Jun N-terminal kinase1/2 (JNK1/2) in cells cultured with and without LPS were measured by ELISA kits. Inhibitors of p38 (SB203580), ERK1/2 (UO1026), JNK1/2 (SP600125), and NF-κB (BAY11-7082) were added to the cultures to evaluate their effects.
Results: Low levels of IL-8 and MCP-1 proteins were detected in the conditioned media in UM cultured without serum. Lipopolysaccharide (0.01-1 μg/mL) increased IL-8 and MCP-1 mRNAs and proteins levels in a dose- and time-dependent manner, accompanied by a significant increase of phosphorylated JNK1/2 in cell lysates and NF-κB in nuclear extracts. Nuclear factor-κB and JNK1/2 inhibitors significantly blocked LPS-induced expression of IL-8 and MCP-1.
Conclusions: This is the first report on the expression and secretion of chemokines by UM. The data suggest that UM may play a role in the pathogenesis of ocular inflammatory diseases.
Chen Y, Jin E, Abdouh M, Bonneil E, Jimenez Cruz D, Tsering T BMC Biol. 2025; 23(1):16.
PMID: 39838458 PMC: 11752652. DOI: 10.1186/s12915-025-02118-w.
Case Reports: Chemokine and Cytokine Profiling in Patients with Herpetic Uveitis.
Nguyen N, Linderman S, Fashina T, Devine M, Conrady C, Shantha J Int Med Case Rep J. 2024; 17:1055-1061.
PMID: 39719962 PMC: 11668311. DOI: 10.2147/IMCRJ.S496941.
Nossol C, Landgraf P, Oster M, Kahlert S, Barta-Boszormenyi A, Kluess J Mycotoxin Res. 2024; 40(2):279-293.
PMID: 38498144 PMC: 11043135. DOI: 10.1007/s12550-024-00528-3.
Gelmi M, Wierenga A, Kroes W, van Duinen S, Karuntu J, Marinkovic M Ophthalmol Sci. 2023; 3(3):100297.
PMID: 37193315 PMC: 10182323. DOI: 10.1016/j.xops.2023.100297.
MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges.
Moustardas P, Aberdam D, Lagali N Cells. 2023; 12(4).
PMID: 36831285 PMC: 9954064. DOI: 10.3390/cells12040617.